A Phase 2 Trial of Zanubrutinib and Venetoclax in Previously Treated CLL/SLL Patients
Latest Information Update: 14 Feb 2025
At a glance
- Drugs Venetoclax (Primary) ; Zanubrutinib (Primary)
- Indications B-cell lymphoma; Chronic lymphocytic leukaemia
- Focus Therapeutic Use
Most Recent Events
- 16 Mar 2022 Status changed from not yet recruiting to recruiting.
- 30 Dec 2021 New trial record